They noticed that DNMT3A mutations in the cytogenetically normal AML patients compared to NPM1- and FLT3-mutated patients (p=0.067 and p=0.065, respectively) were related to remarkably shorter OS and progression-free survival [23]. The gene discussed is NPM1; the disease is acute myeloid leukemia.